Janux Therapeutics Inc
JANX | $48.69 -0.33% -0.33% 670K
|
Professional, Scientific, and T...
(0.0% 1d) (22.2% 1m) (216.0% 1y) (0.0% 2d) (1.5% 3d) (-6.1% 7d) (8.98% volume)
Earnings Calendar: 2024-03-08
Market Cap: $ 2,515,328,321
https://www.januxrx.com
Sec Filling | Patents | 16 employees
(US) Janux Therapeutics is developing safe, effective novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets. The Janux TRACTr development pipeline targets multiple solid tumor indications, including colorectal, gastroesophageal, prostrate, NSCLC, triple negative breast, and ovarian cancers. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response. Combining Janux’s tumor-specific activation with multi-stage anti-tumor signaling has the potential to significantly improve safety, expand the therapeutic dosing window, and maximize patient responses. Janux was founded in the Avalon Ventures accelerator, COI Pharmaceuticals, Inc., in San Diego.
cancer ovarian cancer
add to watch list Paper trade email alert is off
Press-releases
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Published: 2024-02-29 (Crawled : 10:00) - biospace.com/
JANX | $48.69 -0.33% -0.33% 670K
|
Professional, Scientific, and T...
|
| O: 11.86%
H: 5.3%
C: -7.18%
million offering therapeutics
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
Published: 2024-02-20 (Crawled : 15:30) - biospace.com/
JANX | $48.69 -0.33% -0.33% 670K
|
Professional, Scientific, and T...
|
| O: -0.85%
H: 7.22%
C: 6.52%
janx007 janx008 therapeutics
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
Published: 2024-01-08 (Crawled : 16:00) - biospace.com/
JANX | $48.69 -0.33% -0.33% 670K
|
Professional, Scientific, and T...
|
| O: -0.68%
H: 7.08%
C: 5.37%
therapeutics
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
Published: 2023-11-07 (Crawled : 00:00) - biospace.com/
JANX | $48.69 -0.33% -0.33% 670K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 8.96%
C: 4.96%
business therapeutics financial results
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Published: 2023-07-17 (Crawled : 13:00) - biospace.com/
JANX | $48.69 -0.33% -0.33% 670K
|
Professional, Scientific, and T...
|
| O: 3.21%
H: 0.16%
C: -5.75%
offering therapeutics
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
Published: 2023-07-17 (Crawled : 13:00) - biospace.com/
JANX | $48.69 -0.33% -0.33% 670K
|
Professional, Scientific, and T...
|
| O: 3.21%
H: 0.16%
C: -5.75%
janx007 positive update pipeline therapeutics
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
Published: 2023-06-05 (Crawled : 21:00) - biospace.com/
JANX | $48.69 -0.33% -0.33% 670K
|
Professional, Scientific, and T...
|
| O: -0.51%
H: 7.79%
C: 2.65%
therapeutics
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
Published: 2023-04-24 (Crawled : 23:00) - biospace.com/
JANX | $48.69 -0.33% -0.33% 670K
|
Professional, Scientific, and T...
|
| O: 1.04%
H: 0.0%
C: -3.4%
therapeutics
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
Published: 2023-04-20 (Crawled : 23:00) - biospace.com/
JANX | $48.69 -0.33% -0.33% 670K
|
Professional, Scientific, and T...
|
| O: -1.26%
H: 4.01%
C: -0.13%
janx008 tumors trial therapeutics
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
Published: 2023-02-14 (Crawled : 19:00) - biospace.com/
JANX | $48.69 -0.33% -0.33% 670K
|
Professional, Scientific, and T...
|
| O: -2.0%
H: 3.04%
C: -6.75%
care conference health therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10